Search DIAN Data Resource Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-D1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 21 - 30 of 202

Investigator:Helena Chui

Title:Biomarker Characterization of a Novel Truncation Mutation in PSEN1

Date of Request:07/13/2019

Aim 1:To describe CSF profile of AD biomarkers including but not limited to Abeta and tau subspecies in a patient with a novel truncation mutation in PSEN1

Aim 2:To describe imaging characteristics (MRI, FDG, Amyloid PET) of the novel PSEN1 truncation mutation

Investigator:Guoqiao Wang

Title:Select Eligible DIAN-OBS Participants for the DIAN-TU Primary Analysis

Date of Request:07/10/2019

Aim 1:Select Eligible DIAN-OBS Participants for the DIAN-TU Primary Analysis

Investigator:Nick Fox

Title:Psychosis in dominantly inherited Alzheimer’s disease

Date of Request:07/08/2019

Aim 1:To determine the frequency of psychosis in DIAN family members, and to explore associations between psychosis and different genotypes

Aim 2:To examine the relationship between neuropsychiatric symptoms and estimated years to and from cognitive symptom onse

Aim 3:3. To determine if there is a relationship, and any potential interaction, between psychotic symptoms and previously reported risk/modifier alleles (5HT2A receptor polymorphism, SNPs in RP11-541P9.3, ApoE status) and environmental risk factors (e.g. history of substance abuse)

Aim 44. To explore associations between neuropsychiatric symptoms and fluid, imaging and cognitive biomarkers of disease

Investigator:Nick Fox

Title:Longitudinal tau PET in dominantly inherited Alzheimer’s disease

Date of Request:07/04/2019

Aim 1:a) to understand the role tau PET imaging can play as a marker of early Alzheimer’s disease for clinical diagnostic purposes and also as a biomarker in trials of individuals with autosomal dominantly inherited forms of Alzheimer’s disease (ADAD)

Aim 2:b) to optimize static and dynamic methods of tau PET analysis in order to achieve better longitudinal consistency and reduce sources of within-subject variability

Aim 3:c) to improve understanding of when and where tau deposition occurs, and how these relationships change over time;

Aim 4d) to determine the relationship between changes in tau deposition and changes related to neurodegeneration and cognitive decline; and

Investigator:Ben Handen, Bradley Christian, William Klunk

Title:Comparing CSF biomarkers of AD in Down Syndrome and autosomal dominant AD

Date of Request:06/21/2019

Aim 1:To analyze and compare levels of established and novel CSF biomarkers (Aβ40, Aβ42, tTau, pTau, VILIP-1, Ng, SNAP-25, YKL-40, NfL, and sTREM2) between ABC-DS and DIAN cohorts.

Investigator:Randall Bateman and Gil Ribinovici

Title:Comparison between Dominant Inherit Alzheimer Disease and sporadic early-onset Alzheimer’s disease.

Date of Request:06/03/2019

Aim 1:To compare clinical presentation, neuropsychological performance and cognitive decline rate between DIAD and sporadic EOAD.

Aim 2:To examine the regional distribution of tau, amyloid-β, glucose metabolism, and structural atrophy in DIAD and sEOAD.

Aim 3:To determine CSF biomarkers levels and biomarkers rate of change in DIAD and sEOAD.

Investigator:FEI HUA

Title:Development of a robust quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer’s disease and dementia

Date of Request:05/24/2019

Aim 1:Calibrate the QSP model to longitudinal biomarker changes for different mutation status

Aim 2:Virtual patient creation to capture the patient variability

Aim 3:Predict drug treatment effect with virtual patient population

Investigator:Julia TCW

Title:Isogenic APOE isoform glia response to amyloid in brain organoids

Date of Request:05/16/2019

Aim 1:Generation of induced pluripotent stem cells from APP (and/or PS1) mutations

Aim 2:Differentiation of the iPSC to organoids to generate beta-amyloid aggregates and differentiation of isogenic APOE iPSC to microglia

Aim 3:Co-culture isogenic APOE 33 and APOE 44 microglia with the organoids from APP (and/or PS1) mutations

Aim 4Single cell transcriptomic analysis from co-cultured organoids


Title:Protective Factors in DIAN

Date of Request:05/15/2019

Aim 1:Analyze the rates of change in cognition and AD biomarkers in ADAD mutation carriers that are past expected age of onset and are not showing any symptoms

Investigator:Joana B. Pereira

Title:Alterations of the Brain Connectome in Familial Alzheimer's disease

Date of Request:05/14/2019

Aim 1:To define the changes in the structural and functional connectomes in symptomatic and asymptomatic mutation carriers with ADAD

Aim 2:To map these changes as a function of estimated years to onset of AD

Aim 3:To assess whether the connectome alterations are associated with cerebrospinal fluid and blood biomarkers, voxel-wise amyloid, tau and glucose metabolism PET, and clinical measures